Abstract Number: 0987 • ACR Convergence 2020
Efficacy and Safety of Iberdomide in Patients with Active Systemic Lupus Erythematosus: 24-Week Results of a Phase 2, Randomized, Placebo-Controlled Study
Background/Purpose: Iberdomide is a high-affinity cereblon ligand that promotes ubiquitination and proteasomal degradation of Ikaros (IKZF1) and Aiolos (IKZF3), transcription factors linked to the genetic…Abstract Number: 1136 • ACR Convergence 2020
Survey of Medical Cannabis Use in Lupus and Scleroderma
Background/Purpose: Despite the lack of research regarding medical cannabis, marijuana and its by-products have gained popularity over the last decades. A 2019 Statistics Canada report…Abstract Number: 1268 • ACR Convergence 2020
Structural Validity of a Comprehensive Neuropsychological Battery for Assessment of Cognitive Impairment in Systemic Lupus Erythematosus: Exploratory Factor Analysis Confirms Six Cognitive Domains
Background/Purpose: Systemic Lupus Erythematosus (SLE) can lead to neuropsychiatric manifestations including cognitive impairment (CI). The gold standard for assessment of SLE cognitive function is the…Abstract Number: 1284 • ACR Convergence 2020
Application of a Novel Method for Determination of Muscle Mass Relative to Fat Mass in Women with Systemic Lupus Erythematosus and Association with Disability
Background/Purpose: Patients with SLE are at risk for both skeletal muscle loss and increased adiposity, which may predispose to worse health-related quality of life. Decreased…Abstract Number: 1300 • ACR Convergence 2020
Identifying Cognitive Impairment in Patients with Systemic Lupus Erythematosus Using Hidden Markov Models: A Bayesian Approach
Background/Purpose: Cognitive impairment (CI) is usually operationalized on the American College of Rheumatology Neuropsychological Battery (ACR-NB) as a z-score of ≤-1.5 on ≥2 domains or…Abstract Number: 1510 • ACR Convergence 2020
Platelet-bound C4d Is Associated with Platelet Activation and Arterial Thrombotic Events
Background/Purpose: Platelets have a well-defined role in arterial thrombosis, and platelet-bound complement activation products (PC4d) correlate with vascular thromboses in patients with Systemic Lupus Erythematosus…Abstract Number: 1669 • ACR Convergence 2020
Genetics of Age at Diagnosis in Systemic Lupus Erythematosus
Background/Purpose: Genome wide association studies (GWAS) have identified >90 SNPs associated with systemic lupus erythematosus (SLE) risk. However, there may be additional loci impacting the…Abstract Number: 1768 • ACR Convergence 2020
The Importance of Pregnancy Planning in Lupus Pregnancies
Background/Purpose: Given the clinical importance of the pre-conception period in lupus pregnancy management and because pregnancy planning can be potentially improved, this study explores the…Abstract Number: 1798 • ACR Convergence 2020
IgE Anti-dsDNA Antibodies in Systemic Lupus Erythematosus Are Associated with Higher Disease Activity at the Baseline and in Longterm Follow-up
Background/Purpose: Recent reports indicate that autoreactive anti-dsDNA IgE autoantibodies and IgE immune complexes and can activate innate and adaptive immunity leading to amplification of lupus…Abstract Number: 1816 • ACR Convergence 2020
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…Abstract Number: 1832 • ACR Convergence 2020
Barriers to Medication Adherence and Degree of Nonadherence in a Systemic Lupus Erythematosus Outpatient Population
Background/Purpose: It has been reported that 50% to 75% of patients with SLE do not adhere to their medications. However, the reasons for nonadherence are not clear.…Abstract Number: 1980 • ACR Convergence 2020
Understanding the Relationship Between Illness Perceptions and Self-Efficacy Among Latin Americans with SLE Through the Hablemos De Lupus Facebook Page
Background/Purpose: SLE disproportionately strikes Latinos, who are also at high risk for poor outcomes. Self-efficacy (SE) to manage chronic disease correlates with outcomes through self-management…Abstract Number: 0021 • ACR Convergence 2020
Prioritizing Patient Safety While Maintaining Study Integrity During COVID-19: Lupus Intervention Fatigue Trial Modifications and Lessons Learned
Background/Purpose: The coronavirus disease 2019 (COVID-19) global pandemic has drastically impacted the health system and the research community. Many research institutions and funding agencies recommended…Abstract Number: 0253 • ACR Convergence 2020
Serum Albumin as a Predictor of Proteinuria Recovery in Lupus Nephritis
Background/Purpose: Clinical trials and observational studies in lupus nephritis (LN) have shown that proteinuria level at 12 months is the best predictor of long-term renal…Abstract Number: 0270 • ACR Convergence 2020
The New EULAR/ ACR 2019 SLE Classification Criteria: Defining Ominosity in SLE
Background/Purpose: SLE is characterized by different patterns of disease activity throughout its course. Overall, a higher disease activity is an important predictor of mortality and…
- « Previous Page
- 1
- …
- 117
- 118
- 119
- 120
- 121
- …
- 150
- Next Page »